Skip to main content
OpenTrials
Completed

NCT Number: NCT01144611

Efficacy and Safety of Bovine Intestinal Alkaline Phosphatase (bIAP) During Heart Surgery

This multi-centre prospective, randomised, double-blind, placebo-controlled study is designed to evaluate the efficacy and safety of bovine intestinal alkaline phosphatase (bIAP) in reducing the pro-inflammatory post-surgical responses and thereby preserving organ functions in patients undergoing invasive cardiac surgery: combined aortic valve replacement and coronary artery bypass grafting.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Catharina Ziekenhuis, Dept. CardioThoracic Surgery

Eindhoven, 5623 EJ, Netherlands

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or non-pregnant, non-lactating female patients of any race in the ages of >18 years.
  • Patients scheduled for combined aortic valve replacement and CABG surgery.
  • Patients who have given written informed consent prior to participation in the trial and who undertake to comply with the protocol.

Exclusion criteria

  • Patients who are unwilling or unable to be fully evaluated for follow-up.
  • Patients who have base AP levels at > 125 IU/L, or levels < 30 IU/L (ammediol, DEA (diethanolamine) units)
  • Patients who show pre-operative infections or who are suspected of endocarditis or systemic infection.
  • Patients who refuse to accept medically-indicated blood products.
  • Patients who have evidence of significant hepatic disease, including history of clinical signs or laboratory values of total bilirubin > 34.2 µmol/L (> 2.0 mg/dL), ALT (>120) or AST (>135) corresponding to > 3X upper limit of normal.
  • Patients who received investigational drugs in the 30 days prior to study drug administration, or are currently participating in a study during which the administration of investigational drugs within one month is anticipated.
  • Patients who require pre-operative ventilatory support.
  • Patients who have renal insufficiency (history of creatinine >177mol/L or >2.0 mg/dL) or chronic renal failure requiring dialysis.
  • Patients who are planned to receive leukocyte-depletion filtration as part of the bypass circuitry.
  • Patients with severe neurological deficits.
  • Patients who have a recent history of drug or alcohol abuse.
  • Patients with a diagnosis of idiopathic thrombocytopenia.
  • Patients with a history of cancer who have received chemotherapy or radiation therapy within the past 3 months. Patients receiving only adjuvant hormonal therapy are not excluded.
  • Patients who are scheduled to receive "stress doses" of glucocorticoids (i.e., doses >2 mg/kg/day of methylprednisolone or equivalent) prior to, during or following surgery.
  • Patients who are vegetarians or veganists or those patients that may be expected not to be tolerant for bovine proteins.
  • Patients who are, in the opinion of the investigator, unsuitable for the study. A well-documented screening log should be present in the clinic.

Treatment and study plan

bIAP bolus and 8h infusion

Drug

intravenous as a bolus of bIAP (bovine intestinal alkaline phosphatase, 1000 IU) just prior to surgery followed by a 40 IU/kg bIAP infusion during the first 8 hours post surgery.

placebo bolus and 8h infusion

Drug

intravenous as a bolus just prior to surgery followed by an infusion during the first 8 hours post surgery.

Primary outcomes

  1. TNF-alpha

    Time frame: one day before till 5 days post surgery

    as indicator of post-surgical inflammatory response

Secondary outcomes

  1. incidence of new organ dysfunctions

    Time frame: till 30 days post surgery

Sponsors and collaborators

Lead sponsor

Alloksys Life Sciences B.V.

Industry

Collaborators

  • Aix Scientifics

Registry information

Official study title

A Randomized, Double-blind, Placebo-controlled Phase IIIa Study on bIAP, an Anti-inflammatory Moiety, in Patients Undergoing Combined Aortic Valve Replacement and Coronary Artery Bypass Grafting

Acronym: APPIRED-II

Important dates

Study start
2010
Primary completion
2013
Study completion
2013
First posted
Jun 15, 2010
Registry last updated
Sep 20, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.